title: Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
authors.affiliation: Institute of Hematology, University of Rome, La Sapienza, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: G
authors.initials: G
authors.lastname: Avvisati
authors.forename: A
authors.initials: A
authors.lastname: Tafuri
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: S
authors.initials: S
authors.lastname: Amadori
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D010865:Pilot Projects; D013866:Thioguanine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D013866:Thioguanine; D002330:Carmustine; D003630:Daunorubicin